Page 152 - Educacional Ponenecias Congreso SEHH-STH 2020

13. Escribano L, Pérez de Oteyza J, Núñez R, Orfao A. Cladribine induces im- munophenotypical changes in bone marrow mast cells from mastocytosis. Report of a case of mastocytosis associated with a lymphoplasmacytic lym- phoma. Leuk Res. 2002;26(11):1043-6.
14. Dasilva-Freire N,Mayado A,Teodosio C,Jara-Acevedo M,Álvarez-Twose I,Mati- to A, et al. Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis. Int J Mol Sci. 2019;20(3):552.
15. Quintás-Cardama A, Amin HM, Kantarjian H, Verstovsek S. Treatment of aggressive systemic mastocytosis with daclizumab. Leuk Lymphoma. 2010;51(3):540-2.
16. Gotlib J,Baird JH,GeorgeTI,Langford C,Reyes I,Abuel J,et al.A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Adv. 2019;3(15):2264-71.
17. Jeong D, Fauman K, Ross C, Akin C, Mody R. Successful treatment of sys- temic mastocytosis associated with AML-M2, t (8: 21) in a child using MRC- based AML chemotherapy along with gemtuzumab. J Allergy Clin Immunol. 2007;119 (Suppl. 1):S207.
18. Álvarez-Twose I, Martínez-Barranco P, Gotlib J, García-Montero A, Mor- gado JM, Jara-Acevedo M, et al. Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia. Leukemia. 2016;30(8):1753-6.
19. Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omali- zumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol. 2007;119(6):1550-1.
20. Douglass JA, Carroll K, Voskamp A, Bourke P, Wei A, O’Hehir RE. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy. 2010;65(7):926-7.
21. Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014;32(29):3264-74.
22. Galli SJ, Tsai M, Wershil BK, Tam SY, Costa JJ. Regulation of mouse and hu- man mast cell development, survival and function by stem cell factor, the ligand for the c-kit receptor. Int Arch Allergy Immunol. 1995;107(1-3):51-3.
23. Orfao A, García-Montero AC, Sánchez L, Escribano L, REMA. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haema- tol. 2007;138(1):12-30.
24. Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the Europe- an competence network on mastocytosis. Leukemia. 2015;29(6):1223-32.
25. Bibi S, Langenfeld F, Jeanningros S, Brenet F, Soucie E, Hermine O, et al. Mo- lecular defects in mastocytosis: KIT and beyond KIT. Immunol Allergy Clin North Am. 2014;34(2):239-62.
26. Akin C, Brockow K, D’Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild- type or mutated c-kit. Exp Hematol. 2003;31(8):686-92.
27. Álvarez-Twose I, González P, Morgado JM, Jara-Acevedo M, Sánchez-Mu- ñoz L, Matito A, et al. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. J Clin Oncol. 2012;30(12):e126-9.
28. Álvarez-Twose I, Matito A, Morgado JM, Sánchez-Muñoz L, Jara-Acevedo M, García-Montero A, et al. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget. 2017;8(40):68950-63.
29. Hartmann K, Wardelmann E, Ma Y, Merkelbach-Bruse S, Preussner LM, Woolery C, et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology. 2005;129(3):1042-6.
30. De Melo Campos P, Machado-Neto JA, Scopim-Ribeiro R,Visconte V,Tabarroki A, Duarte ASS, et al. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leuk Res. 2014;38(10):1245-51.
31. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004;103(8):3222-5.
32. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560G- Kit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther. 2002;1(12):1115-24.
33. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102(9):3093-6.
34. Verstovsek S,Tefferi A, Cortes J, O’Brien S, García-Manero G, Pardanani A, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008;14(12):3906-15.
35. Hochhaus A, Baccarani M, Giles FJ, le Coutre PD, Müller MC, Reiter A, et al. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J Cancer Res. 2015;141(11):2047-60.
36. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Ef- ficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016;374(26):2530-41.
37. Reiter A, Kluin-Nelemans H, George T, Akin C, DeAngelo D, Hermine O, et al. Pooled Survival Analysis Of Midostaurin Clinical Study Data (D2201+A2213) In Patients With Advanced Systemic Mastocytosis Compared With Historical Controls. Haematologica,2017:S788.
38. Jawhar M, Schwaab J, Naumann N, Horny HP, Sotlar K, Haferlach T, et al. Re- sponse and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood. 2017;130(2):137-45.
39. DeAngelo DJ, George TI, Linder A, Langford C, Perkins C, Ma J, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32(2):470-8.
40. Hartmann K, Gotlib J, Akin C, Hermine O, Awan FT, Hexner E, et al. Midostaurin improves quality of life and mediator-related symptoms in advanced sys- temic mastocytosis. J Allergy Clin Immunol,2020;146(2):356–66.e4.
41. Radia D. Avapritinib, a potent and selective inhibitor of KIT D816V, induces complete and durable responses in patients with advanced systemic masto- cytosis (ADVSM). In Amsterdam,The Netherlands; 2019.
LXII Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia / Ponencias
152